- hace 2 horas
La sanidad en Europa, a debate en The Ring: ¿Sigue siendo un derecho o ya es un negocio?
En esta edición especial de The Ring desde la Cumbre de Salud de 'Euronews', las eurodiputadas Stine Bosse (Renew Europe) y Tilly Metz (Los Verdes/ALE) debaten quién debe costear la innovación sanitaria europea.
MÁS INFORMACIÓN : http://es.euronews.com/2026/03/19/la-sanidad-en-europa-derecho-o-negocio-los-eurodiputados-se-enfrentan-en-the-ring
¡Suscríbete a nuestro canal! Euronews está disponible en 12 idiomas
En esta edición especial de The Ring desde la Cumbre de Salud de 'Euronews', las eurodiputadas Stine Bosse (Renew Europe) y Tilly Metz (Los Verdes/ALE) debaten quién debe costear la innovación sanitaria europea.
MÁS INFORMACIÓN : http://es.euronews.com/2026/03/19/la-sanidad-en-europa-derecho-o-negocio-los-eurodiputados-se-enfrentan-en-the-ring
¡Suscríbete a nuestro canal! Euronews está disponible en 12 idiomas
Categoría
🗞
NoticiasTranscripción
00:07¡Suscríbete al canal!
00:30And who should pay?
00:32Europe is facing spiraling healthcare costs driven by an aging population and chronic diseases.
00:38At the same time, demand for new treatments is growing, raising crucial questions.
00:44Who should pay for healthcare innovation and to what extent is health treated as a business?
00:50One key pressure point is the cost of new drugs and vaccines.
00:54Should the EU coordinate pricing for essential medicines to ensure equal access across member states
01:00while also having tools to intervene in production and distribution during crises?
01:05Or should pricing and supply remain a national responsibility to prevent straining healthcare budgets and weakening market incentives?
01:14Tax debates in the pharmaceutical sector further highlight concerns about how much the industry should profit from public investment.
01:21Europe also faces longer-term challenges.
01:25Its healthcare system spends far more on treatment than prevention.
01:29The real question is not only how Europe will pay for healthcare,
01:33but what kind of healthcare system it ultimately wants to protect.
01:38Let's meet our panelists.
01:41Tilly Metz, a Luxembourgish MEP from the Greens European Free Alliance Group.
01:47She has been a member of the European Parliament since 2018
01:50and serves on the Committee on the Environment, Public Health and Food Safety.
01:55In debates on EU health policy, she has advocated for stronger European cooperation
02:00on public health and greater transparency in the pharmaceutical sector.
02:04We need a strong commitment to solidarity over privatization
02:08and to high-quality care over commercialization, she said.
02:13Stine Boss, a Danish MEP from the Liberal Renew Europe Group.
02:17Elected to the European Parliament in 2024,
02:20she works on economic and industry-related issues
02:23and has spoken about the importance of maintaining Europe's competitiveness
02:26and innovation capacity.
02:28In discussions about the pharmaceutical sector,
02:31she has emphasized the need to balance strong research incentives
02:34with sustainable healthcare systems.
02:36We must do much more, better and cheaper together,
02:40including by creating a single market for clinical trials
02:43and by taking more decisions at the European level, she said.
02:50Welcome. So lovely to have you with us here
02:53for this very special edition of The Ring.
02:55So the idea here, ladies, is to give our viewers back home
02:59a bit of a taste of what exactly you get up to
03:01inside that European Parliament chamber,
03:04here in Brussels and also in Strasbourg.
03:07Sometimes you fire questions at each other,
03:09sometimes it gets a little bit heated.
03:11Today, as you know, we're focusing on healthcare
03:14and the future of it right here in the European Union
03:17and who, of course, should pay.
03:18So, Tilly, if we can start with you on that very, very pertinent question,
03:22who should be paying for the future of healthcare in Europe?
03:25Should it be us, the patients?
03:26Should it be pharma, the governments, big tech?
03:29Yeah, but if we look what the situation is right now,
03:33we see there's a lot of public funding indeed going in research,
03:37but there's also the patient that is paying.
03:40So you could even say that the patient right now is paying twice.
03:43He's paying first with taxes, which go then to funds,
03:49and then he pays again a price at the pharmacy.
03:52So what we need for sure is at the EU level,
03:55but also at national level, more public investment.
03:59Well, it actually all connects.
04:01And I do agree that there is an issue on how do we look into the future?
04:07What is the construction?
04:09Is it all, you know, everybody has access to healthcare,
04:13or is it a different model?
04:15That has to be debated.
04:16But at the end of the day, it all starts and it all ends at the end of the day
04:21that we have a strong and competitive pharmaceutical sector,
04:24and then we can discuss who pays.
04:27And that's an important point, of course.
04:29Tillie Metz, if you look at the data,
04:32one in every two medicines, this is back 25 years ago,
04:35was invented or discovered right here in Europe.
04:38Now it's only one in six.
04:39What went wrong?
04:41Exactly.
04:41I mean, if we go more to privatization
04:44and more leaving all the leadership to the pharma industry,
04:48we see that it doesn't work.
04:50Indeed, we still have innovation in Europe.
04:52We still have, but we are not really scaling up.
04:55But if we look at innovation
04:57and there is no real added value for the patients,
05:00that's something we need to do better.
05:02So it's up to public authorities
05:04to take back their leadership and their responsibility.
05:09I mean, if we go more and more in private health care,
05:13there is a huge risk of even more commercialization
05:17of access to health care
05:19and of commodifying medicines and health care.
05:22Would you agree with that point, Senebos?
05:24Yes, I do agree,
05:25but I don't think that a strong pharmaceutical sector
05:29is the opposite of having a totally sane
05:34and fantastic health care sector as such.
05:36I think these two things go hand in hand.
05:39But that is, of course, a question of funding.
05:41First of all, importantly enough,
05:44funding for the pharmaceutical sector.
05:45And then, of course, who pays?
05:47Is it tax paid?
05:48Is it universal access to treatment and to medicines?
05:52Or is it a private sector that we see growing?
05:55And there, I think, we will have to face
05:58that there will be a blend.
05:59And I am a strong believer in a strong universal health care sector
06:06that makes sure that there is access for everybody.
06:09I mean, we know that the private sector
06:12and the objective of the private sector
06:14are not necessarily aligned with what is really the public health need.
06:20But I agree, we need a strong pharma sector.
06:24We need to have manufacturing back in Europe
06:27and we need to have the conditions.
06:29But the incentives for the pharma industry
06:33must not rely only on intellectual property rights.
06:37There are other models, other alternatives of incentives.
06:41There needs to be a better coordination from the public authority
06:46in order to make it more equal.
06:48And this issue of scaling up, how can we do better here?
06:51I mean, in Europe, we're great at research,
06:53we're great in the lab,
06:54but getting it to market then is always the big challenge.
06:56Yeah, and there I tend to disagree.
06:59So without letting go of the security level for our citizens,
07:04we should base much more on our EMMA
07:08and less on our national entities.
07:11Because if you look at it,
07:13it is 578 days from the approval of a medicine
07:19in EMMA, till it reaches the patient.
07:22And on the European Medicine Agency,
07:24we'll come back to that point.
07:25I didn't say that it should not be the European Medicine Agency.
07:28I'm very pro-European.
07:29On contrary, we need better cooperation between the member states
07:33and that can only be done at European level.
07:36I mean, on that I agree with you.
07:38And is the European Union ready for the next big pandemic?
07:41Because we know it's coming.
07:42I mean, we remember those terrible days of COVID
07:44and we're being warned that the next pandemic is around the corner.
07:47Sinebos, is the EU ready for this?
07:49No.
07:49I mean, we are more prepared than we were.
07:52I mean, we have learned.
07:54And the institutions are also now stronger
07:56and health is a stronger issue.
08:00You know, the fact that we now have the health committee
08:02and it's a full committee and so on.
08:04All these things point in the right direction.
08:05That's not reassuring our viewers, just having a committee.
08:08No, I agree.
08:09And here I'm back to that.
08:11We need also a stronger collaboration between countries within the union.
08:17We need links also for ongoing health care,
08:20not only on the innovation side,
08:22but also on the delivery side, also between the hospitals.
08:26There's so many things that we can do a lot better
08:29and cheaper together if we work pan-European on these subjects.
08:34But I think one thing that we definitely learned from the pandemic
08:37is that we are over-reliant to the pharma industry.
08:41So we need the public sector to take more responsibilities again
08:45and to have a better coordination.
08:47To be too reliant to the pharma industry,
08:50I mean, that gives a lot of insecurities also regarding the supply chain,
08:54regarding the transparency on the real coast on research and development.
08:58I mean, I'm not against a strong pharma industry,
09:02but we must definitely also consider to have a European infrastructure
09:07on research and on production also of medicine.
09:11And I think we need to be ambitious there
09:14in order not to be too reliant and dependent only on the private sector,
09:20where we all agree that they have different objectives
09:24and that is also perfectly okay.
09:26I mean, as I say, they are not necessarily aligned
09:29with what is really an added value of the medication.
09:32That's why there are certain sectors like the orphan medicines,
09:37but also the antibiotics,
09:38where the pharma industry is not really interested
09:41because it's not really financially interested.
09:44So the objectives are different,
09:45and that's why we need a stronger public leadership of public authorities.
09:50That's the view from Thierry Metz.
09:51Let's hear your view there.
09:52You might have recalled that I'm not a socialist,
09:56but I do have a lot of social responsibility
09:59within the way I think about our citizens.
10:02So I cannot see, Tilly,
10:05that we should go for a fantastic publicly owned pharmaceutical sector.
10:11I think we need a strong, privately owned,
10:14privately financed pharmaceutical sector
10:17who can see the benefits of staying in Europe,
10:20developing in Europe, and delivering in Europe.
10:22And we also, of course, want to hear from you.
10:24You can always write to us at TheRing at Eurenews.com.
10:27We'll come back to it.
10:32Now it is time for our viewers to get a real taste of inside the chamber
10:36when MEPs actually fire questions at each other.
10:39So now I'd like you to start with your first question for Thierry Metz.
10:42Well, Thierry, I just want to know
10:45how on earth are you going to make sure
10:48that we can be able from Europe
10:50to deliver the best, the newest medicines,
10:55the fastest to our citizens?
10:58What is your prescription for that?
11:01I think it's very clear that we need to give incentives
11:05to the pharma industry
11:06and, on the other hand,
11:07to have kind of safe net by a public infrastructure.
11:12In order to have innovation
11:14and to guarantee also accessibility to innovation to everybody,
11:19we need to put conditions on this public funding
11:23and we need public authorities to play their role
11:27on asking accountability to the pharma industry
11:31and on asking transparency on the R&D costs,
11:36but also on how they develop their prices.
11:39I mean, as I said at the very beginning,
11:41it cannot be that the patient pays two times or three times,
11:45once by the data, once by the taxes that he pays,
11:48and then again a high price at the pharmacy.
11:52Are you satisfied with that answer
11:53or would you like to follow up?
11:55No, because I still see that there is a high risk
11:59with all your good ideas,
12:00some of them we can agree on,
12:01but there is a high risk
12:02that the pharmaceutical sector would look to other grounds
12:06and say, you know, it's much more attractive to us
12:09to develop and to invest in the U.S., for example.
12:13So, bye-bye.
12:14Do you agree with the U.S. system
12:16where indeed the pharma industry
12:19wants to put very much higher prices?
12:22I mean, that's what they want.
12:23That's why they are attracted by the market in the U.S.
12:25Is that the model that we should aim at?
12:28No.
12:28Where only an elite can offer treatment
12:31and have innovation access and innovative healthcare?
12:35No, I think we must definitely take our responsibility
12:39and that is one of the lessons learned from the pandemic.
12:42And that is, Tina, that's what we are working on,
12:44the Critical Medicines Act.
12:46It's exactly what we are doing there.
12:48We are making that the EU takes more responsibility
12:51in coordination, what is critical medicine for the citizens
12:56and what is really also of an added value
12:59and how we can bring back manufacturing again back to Europe.
13:03That's what we are working on, on the Critical Medicines Act.
13:06And our viewers can read more about that Critical Medicines Act
13:08on yournews.com.
13:09But now, Tilly Metz, it is time for you to address
13:11your very first question, Justine Boss.
13:13Yeah, but my very first question,
13:15I said it already a little bit,
13:16is like, do you agree in order to have accessibility
13:20and affordability on medicine that we need to have more transparency on coast?
13:27And that is meaning when we give public funding to the pharma industry
13:31that we need to put conditions on this public funding.
13:36Conditions like supply chain, transparency on coast, etc.
13:42I think first of all, and I will be repeating myself slightly,
13:45so bear with me, I think that it's the starting point
13:48will be that we have a strong pharmaceutical sector.
13:51And you might not agree, you think you jump right into
13:54it has to be state-owned and it has to be state-funded.
13:57I'm on another page there.
13:59Then having said that, then I agree that there are areas,
14:03the Critical Medicines Act is a good example,
14:05but there are also other areas where we have to think differently
14:09as Europeans, but also as countries.
14:12And that's why this thing about the nearly 600 days to approval,
14:17that we have to get out.
14:19We need to make sure that the country's level of approval is not there.
14:25It doesn't make any difference.
14:27And then on top of that, if we say to ourselves
14:29that there's an 80% difference between the countries
14:32of the accessibility to medicines,
14:35of course that cannot be so.
14:37So we have a huge issue at our hands
14:40to level this out between countries
14:42and to protect our universal health care.
14:45But that is only protected if we have earnings.
14:49Earnings makes taxes.
14:51Taxes makes the money to actually finance health care.
14:55I know you had another long list of questions for each other,
14:58but we will have to wrap it there
14:59because we've now heard from our MEPs
15:02and I would really like to bring in another voice here.
15:08I would like to bring in the voice now of the head of AstraZeneca,
15:12the CEO and Executive Director, that's Pascal Sochiot.
15:15He recently said that the pharma industry in Europe
15:18will be reduced to a shadow of itself within 15 years.
15:22He said this due to two major threats facing the pharma industry.
15:26One, pharma companies are investing heavily in the U.S.
15:29to avoid heavy taxes by the Trump administration.
15:32And of course, the other elephant in the room,
15:34China is of course the leader in generics
15:37and a major competitor when it comes to innovation medicines.
15:40So Tilly Metz, I'm curious to hear your view here
15:43on the concerns of the industry and of the CEO there of AstraZeneca.
15:47First of all, what I want to correct,
15:49because it seems like I want 100% only state-owned pharma industry.
15:55That is wrong.
15:56I just want a safe net that is public
16:00in order to guarantee that we are not 100% lying.
16:04But the pharma industry has an important role to play.
16:09And I spoke about incentives.
16:10I'm just convinced, and we see it in the reality,
16:14if we are pragmatic, we see in the reality,
16:17leaving it all to the pharma industry,
16:19that the system doesn't work
16:20because we have shortage of medicine, etc.,
16:23what I said before.
16:25But we need other incentives,
16:27like the subscription model,
16:29where you know if you work on research,
16:31for example on antibiotics,
16:32that you get the fixed amount of money
16:35in order to work on that.
16:37That is one model.
16:37Or a milestone model.
16:39So, Ancinebos, if I can just bring you in here,
16:43I mean, is it scaremongering what he says there?
16:45Or would you agree with it?
16:46Because, I mean, you're still the home of a big pharma.
16:49And I think it's actually more serious
16:50than we can dream of.
16:52We are, and this is a little bit dramatic,
16:54but it's good on television,
16:56we are under attack.
16:58I mean, our pharmaceutical sector is under attack.
17:01This idea of the most favored nation legislation
17:08that the administration in the U.S. put in place
17:12is really, really hammering us.
17:15And I'm not saying that we should give up,
17:18and I agree with you on the fact
17:20that there should be a basis coverage,
17:22obviously, for citizens in Europe,
17:24also regarding the safety of the approvals.
17:27But we have to understand that we must fight this
17:31with giving terms and conditions
17:34to our pharmaceutical sector
17:36that can compete with this, in my opinion,
17:39very mean model,
17:40and that we have to fight back.
17:42Would you agree with this,
17:43what she calls a very dramatic statement?
17:44Let's look what is at the center of our concerns.
17:47And I am allowing myself to say
17:50that it is different as a politician
17:51than from the pharma industry perspective.
17:54At the center of our concern is the patient.
17:57If you look at the situation of the patients
17:59in the United States,
18:00they are in a much worse health situation.
18:04If you look mental health,
18:05if you look obesity,
18:06if you look at a lot of diseases,
18:09suicide, everything,
18:10they are in a much worse case.
18:12What do I have from innovation
18:14if it's not accessible for the large public?
18:17And in innovation, we are not bad in Europe.
18:20It's in scaling up,
18:21it's in manufacturing where we are leaking.
18:23And we have a very fragmented market as well,
18:25Sinebos.
18:26Sure, we have this fragmented market,
18:28and we have really not a capital union, right?
18:31So we need also the fact that investors
18:34should have a much,
18:36or yeah, investors and companies,
18:37much easier access to capital
18:39to make them stay here.
18:41We also have to face, Tilly,
18:44that no matter how we turn this around,
18:46there needs to be a strong sector here.
18:49We need to understand what the problems is for the sector,
18:52try and solve them,
18:54and then of course fight back to the US,
18:55because I agree,
18:57even long liberty is much better in Europe,
18:59and we should not give up on these areas,
19:01but it's not on the contrary to have a strong sector.
19:05And then it comes back to the first question,
19:07who is paying?
19:08And there I think there is a need for a truly
19:12and deep discussion on transparency,
19:15on how do we actually have fun,
19:17because our model,
19:18look, our model is like 80% gets everything, right?
19:23We covered a lot of people.
19:25That's why we buy a lot of pharmaceutical products
19:28at a cheap price.
19:30In the US, not a lot of people are covered,
19:33so they pay much more per pill.
19:36So that makes it completely uncomparable,
19:38and that we have to sit down
19:40and really investigate and find out,
19:43also in the Biotech Act,
19:44how are we going to solve this?
19:46So you have a lot to do, ladies,
19:48but now it is time, in fact,
19:50for our next round.
20:00Now I'd like to bring in some figures.
20:02There is a big problem
20:03when it comes to Europeans
20:04having to wait for new medicines.
20:06The EU average is about 578 days.
20:10That's from approval to patient access.
20:13And it varies from country to country.
20:15Patients in some countries
20:17have to wait seven times longer than others.
20:20While the fastest is in Germany at 128 days,
20:24Portuguese patients wait the longest.
20:26So your reaction here to this inequality?
20:28Yeah, this is completely how it is.
20:32But, of course, there is an explanation.
20:35It's not because Portugal wants
20:37to have a longer period for the population.
20:41It's about finances.
20:42It's about can they afford it?
20:44And here we are, of course,
20:45entering into very, very difficult discussions
20:48because a country like Denmark,
20:50if you compare us to Bulgaria, to Romania,
20:53then we are in for big, you know,
20:56there's a big difference.
20:57And that we need to, over time, solve.
21:00But one of the ways to do it is to, again,
21:03what we can make better and cheaper together,
21:05we must, including the EMA,
21:07to save all the money in all the countries.
21:10And the irony is in Germany, 128 days,
21:13that's supposed to be quick.
21:14I mean, that's a matter of life and death
21:15if you have to wait that long for your pills.
21:16Yes.
21:17Yeah, indeed.
21:18And what we need also is we need more cooperation
21:22in European procurement so that we do,
21:26that we buy together in order also with strict timeline
21:30and also with the security on the supply chain.
21:33So that's, again, we need to give more incentives.
21:36That is true.
21:37But that goes hands in hand with conditions
21:40of supply chain, et cetera.
21:42And we need, of course, on that I agree with Sinebos,
21:45we need also to keep the EMA,
21:47the European Medicines Agency,
21:49more human resources and more resources in general
21:52in order to be more efficient.
21:54And then that we need less and less also there
21:56to rely on national issues.
21:59And should there be an EU-wide pricing
22:01for essential medicines?
22:03I think at the end of the day,
22:04we will get into that area.
22:06I don't see that we can avoid having some kind of,
22:10you know, more transparency
22:12and more central disgust pricing.
22:15Because now when you go to your doctor,
22:16sometimes they say, go to France,
22:17you can get to France.
22:18Yeah, yeah, yeah, yeah.
22:18Yeah, yeah.
22:19That's why I say, but I had this conversation with,
22:22you can probably guess who it is,
22:23but it was a CEO of a large Danish pharmaceutical company.
22:27And I said to him, I don't worry when I go in a shop
22:31and I buy, like, say, H&M, and I buy something.
22:34And I can see the price in Sweden, in Germany, in France.
22:38I'm still happy paying with my,
22:40unfortunately, it's still Danish kroner.
22:43So I think we should be more transparent.
22:47We should be more bold together with the industry.
22:50And they are also, at least some of them,
22:53maturing in that direction.
22:55Of course, also because of the big threat
22:57that we have just debated from the outside.
23:00Now, we definitely need to put public interest.
23:02It's definitely more important,
23:03especially in the health sector,
23:06than commercial interest.
23:07I mean, at the very end,
23:08the very famous company, pharma industry,
23:11that produced drugs in,
23:12in the last moment,
23:14the price was really increasing again.
23:16Why?
23:16All the research, all the A&D was done.
23:19So we need definitely transparency.
23:20And as I said,
23:21that goes hand in hand with also public funding.
23:25It's something we owe to the taxpayers,
23:28we owe to the citizens,
23:29to ask for this transparency.
23:31And especially when we speak of a fundamental right,
23:34which is access to healthcare.
23:36Because as you said,
23:38twice or three times or four times already here in the program,
23:40consumers are paying twice.
23:42Patients are paying twice.
23:43This is a big problem.
23:44Well, I'm not sure I agree completely
23:46on the fact that people are paying twice.
23:50I agree that there is a debate
23:52on how can we make this more transparent.
23:54But to be honest,
23:55I mean,
23:56the pharmaceutical sector
23:58invests a lot,
23:59and they should.
24:00And I also agree
24:02that in some areas,
24:03they should also be held accountable.
24:05You know,
24:05if there is public money involved,
24:07yes,
24:08I agree on that.
24:09Shall we speak about the benefits
24:10that we made
24:11for the COVID-19?
24:12Yes,
24:13but look,
24:14then on the other hand,
24:15of course,
24:16there is
24:16large number of workplaces,
24:20innovation,
24:21you know,
24:21attracting skilled people,
24:23and all this
24:24is also beneficial for Europe.
24:26It's not only,
24:27it's not a non-sum spill,
24:29you know,
24:30thing.
24:30We have to look at the total.
24:32And I think it is,
24:34it would be devastating
24:35if we lost the last industry,
24:38ladies and gentlemen,
24:39the last industry
24:40where we are still close to,
24:42not even,
24:43but close to on par
24:45with the US and China.
24:47We lost digital industry.
24:49So do we want,
24:51in 10 years from now,
24:52to have a pharmaceutical sector
24:53where we said,
24:53that's history,
24:54it's gone.
24:55And on the digital industry,
24:56that's, of course,
24:56for another episode of The Ring.
24:58We'll have to wrap it up there
24:58because I would love to move on
25:00to the fifth
25:01and very last round
25:02of this very special edition
25:03of The Ring,
25:04which is focusing on
25:05the future of healthcare.
25:10Ladies, are you ready?
25:11Yeah.
25:11Yeah.
25:12Excellent,
25:12because you need
25:13all your wits about you
25:14for this last segment
25:16because it's a little bit different.
25:17You only are allowed answer
25:19using yes or no.
25:21Does that sound good?
25:22That sounds good.
25:23Great.
25:24Let's do it.
25:24Stine Boss,
25:25let's begin with you.
25:26Should the EU cap prices
25:28for essential medicines?
25:29Yes or no?
25:35Can I have a yes but?
25:37Very briefly.
25:38Yes,
25:39but it has to be limited
25:41to very, very special situations
25:43and very special medicines.
25:44Okay,
25:44let's see if you can do
25:45a yes or no here.
25:46Yes,
25:47it's a fundamental right.
25:48Access to fundamental medicines
25:49is a fundamental right.
25:51Another question coming
25:52for you both.
25:53Tilly,
25:53I will start with you.
25:54Should Brussels negotiate
25:55drug prices
25:56for all EU member states?
25:58I think that would be
25:59a strength if we do that.
26:00We saw the COVID-19
26:01that the negotiating together
26:04gives us more power.
26:05So yes.
26:06So that's a yes.
26:06What about you?
26:07Yes or no on this one?
26:08Down the road,
26:09it will be a yes from me also.
26:12Should patients be waived
26:13during major health crises?
26:15Yeah, yeah, of course.
26:16I mean the patients
26:17and this is the...
26:18You say yes, Dino.
26:18I say yes
26:19to the fact that you need,
26:21we need,
26:22we're politicians,
26:23we need to keep our main focus
26:25on the patients.
26:26No doubt about that.
26:27And now a question
26:28you're both going to love.
26:29Should medicines be the same price
26:30all across the European Union?
26:33That's a long way to go there
26:34but that would be coherent
26:37if we listen to the European citizens
26:39that want more healthcare
26:41and also better coordinate.
26:43a resigning yes.
26:44What about you?
26:45I mean it goes hand in hand
26:46with what I just answered.
26:47So if you have a procurement
26:50way down the road
26:51that is common European
26:53then of course you also have
26:54a transparent common...
26:56And just finally,
26:56is the future of EU health
26:58and innovation bright?
27:01Yes.
27:02I'm a strong believer
27:04in the EU as such
27:05and of course also in this sector
27:06but we have to get
27:07a lot of our act together.
27:08And what about you?
27:09Yes or no?
27:09Bright future or not?
27:11Bright future, yes.
27:12Because we should listen
27:13to the citizens
27:14and we should put more funding
27:15and not cut the funding...
27:17Telly Meiss, did you agree
27:17with anything you've heard?
27:18Yes, she said that we should waive
27:20the intellectual property
27:21device during a pandemic.
27:22There you go.
27:23You see it's here on The Ring
27:24where we get people to talk,
27:25disagree and sometimes agree.
27:27Thank you so much
27:28and a round of applause
27:28for our two MEPs on The Ring,
27:30Cine Boss and Tilly Meiss.
27:32Thank you.
27:37And thank you so much
27:38for tuning in.
27:39As always, we love to hear from you.
27:40Write to us at The Ring
27:41at Euronews.com
27:43and stay with us here
27:43on Euronews.
27:45We love you!
27:45¡Gracias!
Comentarios